According to Reuters via Pharmalot, Roche Pharmaceuticals is
expected to post a 33 percent increase in full-year net profit for 2006 to 9.11 billion Swiss francs ($7.33 billion), according to the average of a Reuters poll of 15 analysts. Sales are seen up 17 percent at 41.65 billion francs, with drugs sales 21 percent higher at 32.94 billion francs.
A strong demand this winter for Roche’s flu vaccine Tamiflu is one reason for the higher-than-expected earnings.
If you enjoyed this article, please consider sharing it!
Sign in or Post as Guest
- Comment help
- Get Livefyre
-
Translator
